GLP-1 receptor agonists

Glucagon-like peptide 1 receptor agonists (GLP-1) are a class of incretin-based medications that has profoundly changed the treatment of type 2 diabetes mellitus because they simultaneously address hyperglycemia, body weight, appetite, gastric emptying rate, and, for some agents, cardiovascular and renal outcomes. Unlike dipeptidyl peptidase 4 (DPP-4) inhibitors, which indirectly enhance endogenous incretin signaling, GLP-1 RAs provide direct pharmacological stimulation of the receptor, with stronger clinical effects on glycemic control and especially on weight loss. Their current importance therefore depends not only on their ability to lower glycated hemoglobin, but on their position at the intersection of diabetology, obesity medicine, cardiovascular prevention, and kidney protection.

The class includes agents that differ in structure, half-life, route of administration, dosing frequency, and magnitude of extraglycemic effects. Those most widely used clinically include liraglutide, semaglutide, dulaglutide, exenatide, and lixisenatide, as well as oral semaglutide. Not all agents are equivalent: some have documented reductions in major cardiovascular events, whereas others have primarily demonstrated cardiovascular safety without a clear superiority benefit; some have a very pronounced effect on weight, while others have a more limited effect; some are particularly convenient because of weekly dosing, whereas others require daily administration. Understanding this heterogeneity is essential, because prescribing a GLP-1 RA is not an abstract class choice, but the selection of a specific agent for a defined clinical profile.

GLP-1 receptor agonists were developed as glucose-lowering medications, but over time they have acquired a much broader identity. Initially, their value was linked mainly to their ability to reduce blood glucose with a low risk of hypoglycemia and concomitant weight loss, in marked contrast to medications associated with weight gain or glucose-independent insulin secretion. Subsequently, large cardiovascular outcome trials showed that at least some agents in the class do more than produce biochemical efficacy: they reduce major cardiovascular events in patients with type 2 diabetes mellitus at high risk. More recently, studies such as FLOW and SELECT have further expanded the relevance of the class to chronic kidney disease and cardiovascular protection in obesity, even beyond diabetes.

This broadening of the conceptual indications has profoundly changed the therapeutic hierarchy. Today, selecting a medication for type 2 diabetes mellitus is no longer based solely on lowering glycated hemoglobin, but also on the presence of obesity, atherosclerotic cardiovascular disease, chronic kidney disease, hypoglycemia risk, patient preferences, route of administration, costs, and long-term sustainability. Within this framework, GLP-1 RAs have gained a central role because they combine glycemic control, weight loss, and, for specific agents, prognostic protection. The most recent guidelines therefore place them among the most important classes when a patient has established atherosclerotic cardiovascular disease or when weight management is an integral therapeutic goal.

The transformation of this class also has cultural significance. For many years, diabetology operated within a framework focused almost exclusively on blood glucose. GLP-1 RAs have helped shift attention toward cardiometabolic medicine, in which lowering glycated hemoglobin remains important but does not fully capture the value of a treatment. When an agent helps a patient lose weight, reduces insulin requirements, limits therapeutic inertia, lowers the risk of cardiovascular events, and integrates into a broader program for obesity and overall risk management, its clinical assessment changes radically.

This does not mean that the class has become a universal solution. GLP-1 receptor agonists have genuine limitations: frequent gastrointestinal adverse effects, the need for titration, high cost, variability in individual tolerability, and, for some formulations, the need for injection. Moreover, the class is not homogeneous: cardiovascular benefit is not identical across all agents, the degree of weight loss varies substantially, and structural differences between exendin-4-based molecules and human GLP-1 analogues may affect efficacy and treatment persistence.

Their contemporary role should therefore be interpreted hierarchically. They are not merely medications for hyperglycemia, but a family of treatments that has redefined the relationship among diabetes, obesity, and cardiovascular risk. Precisely for this reason, their prescription requires more discernment, not less: clinicians must know when the class offers a genuine advantage, which agent is consistent with the clinical target, and when other strategies are more appropriate.

Understanding GLP-1 RAs requires starting with the physiology of glucagon-like peptide 1, an intestinal hormone secreted predominantly by L cells in the ileum and colon in response to nutrient intake. GLP-1 is part of the incretin system, the set of neuroendocrine signals linking a meal to the insulin response. Under physiological conditions, it increases glucose-dependent insulin secretion, reduces glucagon secretion when blood glucose is elevated, slows gastric emptying, and contributes to satiety regulation through central and peripheral pathways. This system is dysfunctional in type 2 diabetes mellitus, and pharmacological enhancement of GLP-1 signaling makes it possible to correct several pathophysiological abnormalities simultaneously.

GLP-1 receptor agonists are resistant to rapid degradation by dipeptidyl peptidase 4. After binding to the GLP-1 receptor, they activate intracellular pathways that increase cyclic adenosine monophosphate (cAMP) and modulate glucose-dependent exocytosis of insulin granules. This is crucial because it explains the combination of efficacy and safety: insulin secretion is enhanced mainly when glucose is elevated, so the risk of hypoglycemia remains low unless the medication is combined with insulin or insulin secretagogues.

The effect on glucagon is a second major mechanism. In type 2 diabetes mellitus, glucagon secretion is often inappropriately elevated, maintaining hepatic glucose production even when it is not needed. GLP-1 RAs attenuate this abnormality, thereby helping reduce both postprandial and, indirectly, fasting glucose. The clinical result therefore depends not only on increased insulin secretion, but on correction of a bihormonal dysfunction involving both beta and alpha cells.

A third pathway is the slowing of gastric emptying. This effect is more pronounced with short-acting agents and tends to diminish partially with continued use of long-acting formulations, but it remains important in reducing postprandial glycemic excursions. Food reaches the small intestine more slowly, glucose absorption is spread over time, and the post-meal glycemic peak is reduced. Clinically, this improves glycemic control but also contributes to nausea and early satiety.

The action on the central nervous system and satiety circuits explains the reduction in caloric intake. Through mechanisms involving hypothalamic and brainstem structures, GLP-1 RAs increase satiety, reduce hunger, and favorably affect eating behavior. This feature distinguishes them fundamentally from medications that lower blood glucose without affecting energy balance and accounts for their impact on body weight.

Pharmacodynamically, the class is far from uniform. Short-acting agents, such as lixisenatide and some exenatide formulations, exert a relatively greater effect on gastric emptying and postprandial excursions. Long-acting agents, such as liraglutide, dulaglutide, and semaglutide, provide more continuous receptor stimulation, with stronger effects on glycated hemoglobin, body weight, and, in some cases, cardiovascular outcomes. This distinction explains why agents within the class cannot simply be considered interchangeable.

There are also structural differences. Exenatide is derived from the exendin-4 sequence, whereas liraglutide, semaglutide, and dulaglutide are modified human GLP-1 analogues designed to prolong half-life. The molecular strategies used to achieve this include albumin binding, increased affinity for plasma proteins, and greater enzymatic resistance. These modifications are not merely chemical; they influence dosing frequency, potency, tolerability, and persistence of effect.

This leads to a precise pathophysiological conclusion. GLP-1 RAs are not simply glucose-lowering agents, but integrated modulators of postprandial and energy homeostasis. They correct the insulin response, reduce glucagon, slow gastric transit, and modify central appetite regulation. Their clinical impact therefore extends well beyond blood glucose values and fits within a broader view of diabetes as a systemic cardiometabolic disorder.

The patient who derives the greatest benefit from a GLP-1 receptor agonist is often a person with type 2 diabetes mellitus associated with overweight or obesity, who needs improved glycemic control without increasing hypoglycemia risk and has a concurrent goal of reducing body weight. In this population, the class offers an advantage that is difficult to match with other non-insulin medications because it combines a glucose-lowering effect with reduced caloric intake. This is why GLP-1 RAs have assumed a major role in managing the diabetes-obesity phenotype.

A second major clinical profile is the patient with established atherosclerotic cardiovascular disease or high cardiovascular risk, especially when the selected agent belongs to the group with demonstrated benefit on major events. Liraglutide, subcutaneous semaglutide, and dulaglutide have shown in their respective trials a reduction in cardiovascular risk that extends beyond the improvement in glycated hemoglobin. This does not justify using every GLP-1 RA as though it had the same level of evidence, but it makes the class highly attractive when the patient has a history of myocardial infarction, stroke, peripheral artery disease, or a particularly high overall risk profile.

Another relevant profile is the patient with diabetic kidney disease or chronic kidney disease, in whom GLP-1 RAs may provide metabolic benefits and, for some agents, a structural renal benefit. In this setting, their role should be viewed in relation to, rather than in opposition to, sodium-glucose cotransporter 2 inhibitors. Although the latter hold a dominant position in kidney protection, semaglutide nevertheless showed clinically relevant slowing of major renal outcomes in the FLOW trial, further broadening the class profile in this field.

GLP-1 RAs are also particularly useful when early insulin intensification is to be avoided. In a patient with type 2 diabetes mellitus inadequately controlled with oral therapy, but without catabolism, ketosis, or severe hyperglycemic symptoms, introducing a GLP-1 receptor agonist may improve blood glucose, promote weight loss, and delay the need for more complex insulin regimens. This strategy has acquired substantial practical importance because it corrects glycemic control without incurring the metabolic cost of the weight gain often associated with insulin.

There are, however, situations in which the class is less suitable. It is not the appropriate choice in type 1 diabetes mellitus, diabetic ketoacidosis, or circumstances in which rapid control of hyperglycemia requires insulin. It is less advantageous when the patient is lean, highly symptomatic, or intolerant of gastrointestinal adverse effects. It should also be assessed cautiously in people with a history of pancreatitis or significant gastroparesis, conditions in which the benefit-risk balance may become unfavorable.

In practice, the truly ideal patient is not simply “someone with type 2 diabetes,” but a person with a combination of needs aligned with the strengths of the class: a need to lower blood glucose, a desire or clinical need to lose weight, little tolerance for hypoglycemia, an interest in documented cardiovascular benefit, and willingness to use a treatment that requires titration and monitoring of gastrointestinal adverse effects.

The efficacy of GLP-1 RAs for glycemic control is, on average, greater than that of DPP-4 inhibitors and, in many circumstances, comparable or superior to other non-insulin therapies. The reduction in glycated hemoglobin varies according to the agent, dose, baseline value, beta-cell reserve, and concomitant therapy, but overall the class ranks among the most effective non-insulin medications. The most potent agents, such as semaglutide, have shown particularly robust reductions in glycated hemoglobin, whereas older or short-acting compounds exert a more postprandial-focused effect.

The true distinguishing feature of the class, however, is its effect on body weight. Unlike sulfonylureas, meglitinides, insulin, and thiazolidinediones, GLP-1 RAs promote weight loss that is often clinically significant. This effect depends primarily on reduced appetite and increased satiety, with a secondary contribution from delayed gastric emptying. Not all agents have the same intensity: semaglutide and, to a substantial extent, liraglutide have shown a more pronounced effect on weight than exenatide or lixisenatide. It is precisely this ability to act simultaneously on blood glucose and adiposity that explains why the class has become strategic in type 2 diabetes mellitus associated with obesity.

The risk of hypoglycemia remains low unless the medication is combined with insulin or insulin secretagogues. This results from the glucose-dependent mechanism of insulin stimulation. Clinically, the advantage is substantial in older or frail patients, or in those whose work and lifestyle would make hypoglycemia particularly harmful. The class therefore provides a favorable balance between efficacy and safety, provided concomitant therapies are adjusted appropriately.

Comparison with other classes helps define their value more clearly. Compared with metformin, GLP-1 RAs do not replace its historic universal role, but they surpass it when body weight and cardiovascular risk become dominant priorities. Compared with sulfonylureas, they provide fewer hypoglycemic events and weight loss, often with better long-term metabolic sustainability. Compared with DPP-4 inhibitors, they have markedly greater glycemic and weight efficacy. Compared with SGLT2 inhibitors, the comparison is not absolutely hierarchical but functional: GLP-1 RAs are particularly strong for weight and atherosclerotic disease, whereas SGLT2 inhibitors have a very strong position in heart failure and kidney protection.

This comparative perspective is essential because it avoids a common error: selecting the class only according to the magnitude of glucose reduction. In contemporary cardiometabolic patients, the correct question is not merely “how much does it lower glycated hemoglobin?” but “which set of problems does it address most effectively?” In this respect, GLP-1 RAs are particularly competitive because they act on several clinically relevant dimensions. Their limitation is not lack of efficacy, but gastrointestinal tolerability, cost, and the need to identify the most appropriate agent precisely.

The evolution of the class has been driven by major cardiovascular outcome trials. LEADER showed that liraglutide reduces major cardiovascular events in patients with type 2 diabetes mellitus at high risk. SUSTAIN-6 also demonstrated cardiovascular benefit with subcutaneous semaglutide. REWIND documented an event reduction with dulaglutide in a broad population that included a relatively high proportion of patients without prior overt cardiovascular disease. These three trials defined the strongest core of the class in terms of protection against atherosclerotic events.

Not all compounds, however, have shown the same strength of signal. ELIXA with lixisenatide and EXSCEL with extended-release exenatide primarily confirmed cardiovascular safety, without an equally clear superiority benefit for the main ischemic composite endpoint. Oral semaglutide initially demonstrated cardiovascular noninferiority in the PIONEER 6 trial; subsequently, the SOUL trial documented a significant reduction in major cardiovascular events compared with placebo. This is essential because the class must be interpreted selectively: cardiovascular benefit is documented for some agents, but it is incorrect to assign the same strength of evidence mechanically to all GLP-1 RAs.

On the renal side, GLP-1 RAs have long shown favorable signals for albuminuria and progression of certain composite endpoints, but the evidence was strengthened by the FLOW trial, in which semaglutide reduced the risk of clinically important kidney outcomes and cardiovascular death in patients with type 2 diabetes mellitus and chronic kidney disease. This does not negate the dominant role of SGLT2 inhibitors in kidney protection, but it broadens the clinical scope of GLP-1 RAs and confirms that their significance extends beyond glycemic control.

Even more interesting from the perspective of cardiometabolic biology is the SELECT trial, in which semaglutide 2.4 mg reduced major cardiovascular events in people with overweight or obesity and cardiovascular disease, even without diabetes. This result is important because it suggests that part of the benefit of GLP-1 signaling does not depend solely on correcting hyperglycemia, but on broader modification of cardiometabolic risk through weight loss, reduced inflammation, hemodynamic improvement, and probable indirect effects on hepatic and vascular metabolism.

The clinical significance of this evidence is very clear. GLP-1 RAs are not merely cardiovascularly safe medications; some agents in the class are prognostically active. This changes everyday prescribing. In a patient with type 2 diabetes mellitus and a prior atherothrombotic event, selecting an agent with demonstrated cardiovascular benefit is not a cosmetic detail, but a decision that may affect the patient's clinical course. Agent selection therefore becomes part of the secondary prevention strategy, not merely correction of glycated hemoglobin.

The GLP-1 RA class is intrinsically heterogeneous, and this heterogeneity is clinically decisive. Liraglutide is a once-daily human GLP-1 analogue, widely used in diabetes and historically important because of cardiovascular risk reduction data from the LEADER trial. It has a good effect on glycated hemoglobin and weight, but the need for daily injection may reduce adherence in some patients. EMA regulatory information identifies it as an option for monotherapy when metformin is inappropriate or in combination with other antidiabetic medications.

Semaglutide is one of the most potent agents in the class. It is available as a once-weekly subcutaneous formulation and an oral formulation. The subcutaneous form has shown strong efficacy for glycated hemoglobin, body weight, and cardiovascular outcomes; more recently, it also demonstrated renal benefit in the FLOW trial. The oral formulation increases therapeutic flexibility, but requires strict administration procedures and has more delicate pharmacokinetics related to absorption with the enhancer sodium N-[8-(2-hydroxybenzoyl)amino] caprylate. In practical terms, semaglutide is often the reference agent when the priority is to combine metabolic efficacy with a substantial effect on weight.

Dulaglutide is a once-weekly GLP-1 receptor agonist with high ease of use and robust cardiovascular outcome data from the REWIND trial. Its simple dosing and good glycemic efficacy make it a highly valued choice for patients who prefer infrequent therapy with a low management burden. EMA also indicates it for adults and patients aged 10 years and older with inadequately controlled type 2 diabetes mellitus.

Exenatide and lixisenatide belong to the group of compounds derived from or inspired by exendin-4 and now occupy a less central clinical position than the major newer-generation human analogues. Extended-release exenatide demonstrated cardiovascular safety in the EXSCEL trial without statistically established superiority for the primary composite outcome. In the ELIXA trial, lixisenatide confirmed cardiovascular neutrality in patients with a recent acute coronary syndrome. These agents retain a possible role, but their use has narrowed in view of the overall superior performance of liraglutide, dulaglutide, and especially semaglutide.

In practical terms, the most relevant differences concern dosing frequency, glycemic potency, magnitude of weight loss, quality of evidence for cardiovascular benefit, and individual tolerability. For this reason, medication selection should never be reduced to the simple fact that “it is a GLP-1.” It is often more appropriate to ask whether the patient needs an agent with the greatest effect on weight, the strongest cardiovascular evidence, the simplest dosing, or the most realistic access within the available prescribing setting.

• Liraglutide: daily administration, extensive clinical experience, demonstrated cardiovascular benefit.
• Subcutaneous semaglutide: weekly administration, high efficacy for glycated hemoglobin and weight, cardiovascular benefit, and relevant renal data.
• Oral semaglutide: a non-injectable option, but with stricter administration requirements and a specific practical profile.
• Dulaglutide: weekly administration, good ease of use, demonstrated cardiovascular benefit.
• Exenatide and lixisenatide: genuine incretin efficacy but a more selective role today, with data primarily supporting cardiovascular safety.

This within-class variety is one reason why the class must be interpreted with great precision. Referring to GLP-1 RAs as an undifferentiated group is useful for teaching purposes, but insufficient for prescribing. The actual clinical decision concerns the right agent for the right patient.

In clinical practice, GLP-1 RAs are used mainly as second-line therapy or for early intensification, but in selected patients they may occupy a very early position in the treatment pathway, particularly when obesity and cardiovascular risk are central features at diagnosis or soon thereafter. The ADA 2026 guidelines emphasize that, in people with atherosclerotic cardiovascular disease, chronic kidney disease, or a need for weight loss, treatment selection may be guided directly by these comorbidities, without rigidly following a fixed historical sequence based only on metformin.

Combination with metformin is among the most rational and common strategies. Metformin primarily reduces hepatic glucose production and improves the overall metabolic context, while the GLP-1 RA adds incretin enhancement, weight loss, and reduction of postprandial glucose. This combination is often particularly effective in patients with overweight and inadequate control.

Combination with SGLT2 inhibitors is now one of the most interesting strategies because the two classes have complementary mechanisms and partially overlapping but nonidentical benefit profiles. SGLT2 inhibitors are particularly effective in heart failure and kidney protection, whereas GLP-1 RAs have a major effect on weight and, for some agents, a strong position in atherosclerotic prevention. Their combination may be especially rational in patients at high cardiometabolic risk.

Combination with basal insulin is another very important use. In patients who do not achieve the target with oral therapy, but in whom rapid progression to basal-bolus insulin regimens is to be avoided, a GLP-1 RA can be added to basal insulin to improve postprandial glucose, reduce weight or limit weight gain, and lower insulin requirements. In many patients, this strategy is more favorable than insulin intensification alone.

Combination with sulfonylureas or with already substantial insulin doses requires particular attention, because the class's low hypoglycemia risk may diminish if concomitant treatment continues to lower glucose in a non-glucose-dependent manner. In these cases, it is often appropriate to review the doses of the associated medications.

Routine combination of a GLP-1 receptor agonist with a DPP-4 inhibitor, by contrast, is generally not appropriate. Both treatments act on the same incretin axis, but the GLP-1 RA already provides much stronger direct pharmacological receptor stimulation; adding a DPP-4 inhibitor therefore produces little or negligible additional benefit at the cost of greater expense and complexity. Guidelines generally discourage this combination.

The appropriate positioning of GLP-1 RAs in modern guidelines can be summarized simply: they are among the preferred options when a patient has obesity, atherosclerotic cardiovascular disease, or when hypoglycemia and weight gain are to be avoided; they are less suitable as sole therapy in severe or catabolic hyperglycemia, when insulin remains necessary.

One of the most important aspects of GLP-1 RA management is gradual titration. Most agents are started at a low dose and increased progressively, not because the starting dose is sufficient for glycemic control, but to improve gastrointestinal tolerability. This principle is also well documented in regulatory prescribing information. For example, with subcutaneous semaglutide, an initial dose of 0.25 mg weekly is followed after several weeks by an increase to 0.5 mg and, if necessary, higher doses. Titrating too quickly increases the risk of nausea, vomiting, and early discontinuation.

Initial monitoring should focus on three aspects: glycemic efficacy, gastrointestinal tolerability, and adherence. Nausea, early satiety, dyspepsia, vomiting, and diarrhea are the most frequent adverse effects and the main reason for treatment discontinuation. In most cases, these symptoms are most pronounced during the first weeks and tend to diminish over time, especially when patients receive appropriate instructions regarding smaller meals, slower food intake, and adherence to the titration schedule.

Glucose monitoring should be tailored to the therapeutic context. In patients receiving monotherapy or combinations with medications that do not cause hypoglycemia, the risk of hypoglycemia is low, so follow-up can focus primarily on glycated hemoglobin, body weight, and symptoms. If the GLP-1 RA is added to insulin or sulfonylureas, home glucose monitoring becomes more important to identify the need to reduce doses of concomitant medications.

Weight reassessment is an integral part of follow-up. If the patient does not lose weight or achieve any meaningful glycemic benefit after an adequate interval, possible poor adherence, unchanged diet, incomplete titration, insufficient dose, or simply a limited individual biological response should be considered. The class is potent, but not all individuals respond with the same intensity.

Another practical issue concerns treatment continuity. Shortages of certain products, also documented in recent regulatory communications, have shown that switching from one agent to another or from one brand to another requires clinical attention, patient education, and closer glucose monitoring. This is particularly true for products that are not bioequivalent or that use different doses and delivery devices.

Finally, follow-up must be dynamic. GLP-1 RAs are medications that should be assessed over time not only by the reduction in glycated hemoglobin, but by their ability to remain sustainable. A highly effective but poorly tolerated treatment does not achieve its purpose. Conversely, a well-tolerated agent that is too weak for the clinical goals should be replaced or combined with another therapy. Optimal management of the class consists precisely in finding the balance among potency, tolerability, adherence, and consistency with the patient's cardiometabolic profile.

The main limitation of GLP-1 RAs is gastrointestinal adverse effects. Nausea, vomiting, diarrhea, constipation, and a sense of fullness are common, especially during the initial phases, and may compromise adherence. Although these effects diminish with continued treatment in many patients, a substantial proportion discontinue or decline therapy specifically because of gastrointestinal intolerance. This should always be discussed before treatment begins, because appropriate expectations improve persistence.

There are also well-recognized areas requiring caution. In patients with a history of pancreatitis, the benefit-risk balance should be assessed carefully. Regulatory information also emphasizes caution in the presence of severe gastroparesis, because the class slows gastric emptying. Specific contraindications may differ among agents and regulatory jurisdictions, but the general principle is that the medication should not be used casually in patients with severe gastrointestinal disorders or symptoms suggestive of ongoing pancreatitis.

Regarding ophthalmic safety, it should be remembered that in SUSTAIN-6, rapid glycemic improvement with semaglutide was associated with an increase in diabetic retinopathy complications in a subgroup of high-risk patients, probably related to the speed of correction rather than direct retinal toxicity. This finding does not preclude use of the agent, but suggests caution in patients with advanced retinopathy and a large anticipated decrease in blood glucose.

The long-term role of the class nevertheless remains very strong. GLP-1 RAs have redefined the treatment of type 2 diabetes mellitus because they lie at the intersection of glucose metabolism, weight control, and event prevention. The future challenge is not so much to demonstrate whether the class works, which is now established, but to determine which agent, in which phenotype, and in which combination produces the greatest benefit. The emergence of next-generation incretin therapies and multi-receptor agonists does not diminish the value of GLP-1 RAs, but redefines their positioning in an increasingly sophisticated therapeutic landscape.

Overall, GLP-1 receptor agonists are among the most important classes in contemporary diabetology. Their value lies not only in lowering blood glucose, but in modifying the patient's cardiometabolic profile more broadly. When selected appropriately, titrated correctly, and integrated into a comprehensive strategy, they represent a treatment with high clinical value. When prescribed without considering tolerability, real goals, and within-class differences, however, the risk is to use an effective class poorly. Rigorous personalization therefore remains essential.